Gregg Early

GS Early has been an award-winning financial writer and editor for nearly three decades, working with many of the leading financial editors and publishers during that time. He continues to work with leading investment editors.
After working as a financial journalist for American Banker, Bond Buyer, and others covering the SEC, MSRB, Supreme Court, and various Congressional finance committees, he became Editorial Director and Vice-President of a leading financial advisory publishing firm.

It was there he built an editorial department that won dozens of SIPA Editorial Excellence Awards for quality journalism. Over the decades, Gregg has built products for several industry superstars as well as some of the brightest newcomers in the business.

His personal top beats are fintech, emerging technologies, biotech, ESG, and green tech. He also has deep experience in all facets of the markets including cryptocurrencies and derivatives. His work and his editors were regularly featured on CNBC, CNN, and Bloomberg, as well as in The New York Times, Washington Post, Wall Street Journal, Businessweek, and other media. He was also a regular moderator and speaker at MoneyShow conferences for decades.

Gregg is a graduate of James Madison University and currently resides in Charlottesville, VA.

Recent Articles

It Might Finally Be Time to Buy Bitcoin

Bitcoin is growing up and becoming a more respectable virtual currency, but it's still not for the faint of heart.

The Best Play in Biotechs: M&A

Investors in biotech stocks have much to look forward to as Big Pharma increasingly looks to shore up its pipelines via M&A.

SPHRY: Starpharma Is Leading the Field With Dendrimers

Starpharma's VivaGel is just starting to make its way into products across the globe, which means big things lie ahead for this Australian biotech stock.